Market Overview

Pfizer Confirms License of Families of Spinal Muscular Atrophy Quinazoline Drug Program from Repligen

Related RGEN
Earnings Scheduled For August 11, 2014
2 Biotech Stocks That Crushed On Earnings
Related PFE
UPDATE: Protalix Shares Spike Higher on FDA Approval of Pediatric Indication for ELELYSO(TM) for Injection, for IV Use for Treatment of Type 1 Gaucher Disease
Fast Money Picks For August 28
Treasury Develolping Options to Curb Inversions (Fox Business)

Repligen Corporation (NASDAQ: RGEN) announced today that it has entered into an exclusive worldwide licensing agreement with Pfizer Inc. (NYSE: PFE) to advance Repligen's spinal muscular atrophy (SMA) program, originally in-licensed from Families of SMA (FSMA).

Posted-In: News FDA

 

Related Articles (RGEN + PFE)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters